

European registry evaluating management practices and pharmacological treatment outcomes in patients with LUTS/BPH.

European LUTS/BPH Registry

Gepubliceerd: 15-09-2009 Laatste bijgewerkt: 18-08-2022

This is a registry conducted within a sample of European Union (EU) general practitioner (GP) outpatient clinics and urologist's hospital or office based clinics. The registry aims to collect real-life data across the different countries on: 1....

Ethische beoordeling	Positief advies
Status	Werving gestopt
Type aandoening	-
Onderzoekstype	Observationeel onderzoek, zonder invasieve metingen

Samenvatting

ID

NL-OMON27526

Bron

Nationaal Trial Register

Verkorte titel

EVOLUTION REGISTRY

Aandoening

Lower Urinary Tract Symptoms associated with Benign Prostatic Hyperplasia

Ondersteuning

Primaire sponsor: European Association of Urology Research Foundation (EAU-RF)

Overige ondersteuning: GlaxoSmithKline Pharmaceuticals

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

Proportion of patients with symptom persistence (defined as IPSS ≥ 8 points) at Month 24 in each country.

Toelichting onderzoek

Achtergrond van het onderzoek

This is a registry conducted within a sample of European Union (EU) general practitioner (GP) outpatient clinics and urologist's hospital or office based clinics. The registry aims to collect real-life data across the different countries on i) the usual management of Lower Urinary Tract Symptoms associated with Benign Prostatic Hyperplasia (LUTS/BPH), ii) the effect of LUTS/BPH and its pharmacological treatment outcomes on LUTS/BPH-related health status, general quality of life (QoL), and sexual function.

Doel van het onderzoek

This is a registry conducted within a sample of European Union (EU) general practitioner (GP) outpatient clinics and urologist's hospital or office based clinics. The registry aims to collect real-life data across the different countries on:

1. The usual management of Lower Urinary Tract Symptoms associated with Benign Prostatic Hyperplasia (LUTS/BPH);
2. The effect of LUTS/BPH and its pharmacological treatment outcomes on LUTS/BPH-related health status, general quality of life (QoL), and sexual function.

Onderzoeksopzet

1. FPI planned: DEC 2009;
2. LPI planned: DEC 2010;
3. LPO planned: DEC 2012.

Onderzoeksproduct en/of interventie

No intervention. Observational.

Contactpersonen

Publiek

Christien Caris
[default]
The Netherlands

Wetenschappelijk

Christien Caris
[default]
The Netherlands

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

A patient will be considered eligible for inclusion in this registry only if all of the following criteria apply:

1. Males, aged ≥50 years;
2. Patients with LUTS/BPH presenting to the GP or urologist who are either:
 - A. Presently/recently untreated with pharmacological agents for LUTS/BPH and with an IPSS ≥8 starting LUTS/BPH pharmacological treatment at or directly after the baseline visit, and fulfilling one of the following criteria:
 - a. Newly diagnosed;
 - b. Previously managed with watchful waiting;
 - c. Discontinued LUTS/BPH pharmacological treatment prior to the baseline visit for the following period:
 - Blockers or phytotherapy or anticholinergics for ≥ 1 month;
 - 5ARIs either as monotherapy or in combination for ≥ 6 months;
 - Other LUTS/BPH medical therapy for ≥1 months;

OR

B. Presently/recently treated with pharmacological agents for LUTS/BPH prior to the baseline visit for the following period, and will continue LUTS/BPH pharmacological treatment:

- a. Blockers or phytotherapy or anticholinergics for $\geq$ 1 month;
- b. 5ARIs either as monotherapy or in combination for $\geq$ 6 months;
- c. Other LUTS/BPH medical therapy for $\geq$ 1 months.

3. Patient has given written informed consent to take part in the registry for a period up to 2 years;

4. Patient is capable of understanding and completing the questionnaires.

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

A patient will not be eligible for inclusion in this registry if any of the following criteria apply:

- 1. Patients with other pathological or metabolic conditions that might explain the LUTS (e.g. bladder infection, chronic cystitis, bladder/prostate cancer, bladder stones);
- 2. Patients in whom the decision has been taken at baseline visit to manage them with watchful waiting or other than pharmacological LUTS/BPH therapy;
- 3. Patients with previous history of prostate cancer;
- 4. Patients who are participating, or have participated in the last 6 months, in any interventional clinical trial;
- 5. Patients planning to move to another part of the country or abroad which indicates that they need to discontinue participation prior to the total follow up of 2 years;
- 6. Patients previously treated with minimal invasive or surgical treatments for their LUTS/BPH or surgical treatments involving the bladder, prostate or urethra;
- 7. Patients with a history or current illness (including psychiatric) that, in the opinion of the investigator, might confound the results of the registry.

Onderzoeksopzet

Opzet

Type:	Observationeel onderzoek, zonder invasieve metingen
Onderzoeksmodel:	Parallel
Toewijzing:	Niet-gerandomiseerd
Blinding:	Open / niet geblindeerd
Controle:	N.v.t. / onbekend

Deelname

Nederland	
Status:	Werving gestopt
(Verwachte) startdatum:	26-05-2009
Aantal proefpersonen:	2000
Type:	Werkelijke startdatum

Ethische beoordeling

Positief advies	
Datum:	15-09-2009
Soort:	Eerste indiening

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

Geen registraties gevonden.

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL1897

Register

NTR-old

Ander register

ISRCTN

ID

NTR2013

: N/A

ISRCTN wordt niet meer aangevraagd.

Resultaten

Samenvatting resultaten

N/A